DGAP-News: Epigenomics AG: Epigenomics Establishes American Depositary Receipt (ADR) Program
(firmenpresse) - DGAP-News: Epigenomics AG / Key word(s): Miscellaneous
Epigenomics AG: Epigenomics Establishes American Depositary Receipt
(ADR) Program
09.07.2013 / 15:00
---------------------------------------------------------------------
Epigenomics Establishes American Depositary Receipt (ADR) Program
- Epigenomics ADRs can be traded on US over-the-counter (OTC) market
effective as of July 9, 2013
- ADR ticker symbol EPGNY
- 1 ADR represents 5 ordinary company shares
Berlin, Germany, and U.S.A., July 9, 2013 - Epigenomics AG (Frankfurt Prime
Standard: ECX), the German-American cancer molecular diagnostics company,
today announced that the Company has established a Level 1 ADR program in
the U.S.A. BNY Mellon has been appointed as the depositary bank for the ADR
program. ADRs of Epigenomics are US dollar negotiable certificates
representing ordinary shares of the Company at a ratio of five ordinary
shares to one Epigenomics ADR. Epigenomics ADRs can be traded on the US OTC
market effective as of July 9, 2013 under the ticker symbol EPGNY. Ordinary
Epigenomics shares are traded in Frankfurt Prime Standard, Germany, under
the ticker symbol ECX.
'In the light of our focused US strategy and the upcoming decision about
the approval of our blood-based test for the early detection of colorectal
cancer, Epi proColon(R), we experience growing interest of US investors,'
explained Dr. Thomas Taapken, CEO/CFO of Epigenomics AG. 'We established
the ADR program as a service to offer those investors an easy way to buy
our shares and to consequently broaden the shareholder base in our core
market.'
- Ends -
Contact Epigenomics AG
Antje Zeise, Manager IR | PR
Epigenomics AG
Kleine Präsidentenstrasse 1
10178 Berlin
Tel. +49 (0) 30 24345 368
ir(at)epigenomics.com
www.epigenomics.com
For US press inquiries:
Epigenomics, Inc.
9700 Great Seneca Highway Rockville
Maryland 20850
pr(at)epigenomics.com
About Level 1 American Depositary Receipt (ADR) Program
The Level 1 ADR program allows US investors to trade shares in the form of
securities from companies that are not listed in the US. ADRs represent
ordinary shares of a company at a certain ratio. They are traded on the US
over-the-counter (OTC) market and are issued according to the demand
(Unsponsored) or in cooperation with one designated depositary bank that
acts as the transfer agent (Sponsored). The price generally tracks the
price of the foreign security in its home market, adjusted for the ratio of
ADRs to foreign company shares.
About Epigenomics
Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in Europe
and is in development for the U.S.A. The Company's technology and products
have been validated through multiple partnerships with leading global
diagnostic companies and testing laboratories. Epigenomics is an
international company with operations in Europe and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
End of Corporate News
---------------------------------------------------------------------
09.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir(at)epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
220422 09.07.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.07.2013 - 15:00 Uhr
Sprache: Deutsch
News-ID 276693
Anzahl Zeichen: 4584
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Epigenomics AG: Epigenomics Establishes American Depositary Receipt (ADR) Program"
steht unter der journalistisch-redaktionellen Verantwortung von
Epigenomics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
